Carbon Monoxide Blood and DNA Biorepository
The purpose of this biorepository is to collect blood from patients at the time of CO poisoning and at follow-up visits months to years later. These samples can be used in the future to learn more about how CO damages the heart and brain and whether blood tests could predict which patients will have problems after CO poisoning.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Carbon Monoxide Blood and DNA Repository|
- Biorepository for serum and plasma [ Time Frame: Within 24 hours of CO Poisoning ] [ Designated as safety issue: No ]Serum and plasma from blood collected within 24 hours of acute CO poisoning
- Serum and plasma (sub-acute) [ Time Frame: 4 weeks to 4 months after CO poisoning ] [ Designated as safety issue: No ]Serum and plasma collected 4 weeks to 4 months after poisoning
- DNA Sequestration [ Time Frame: 24 hours to 12 months after CO poisoning ] [ Designated as safety issue: No ]DNA sequestered from blood drawn up to 1 year from CO poisoning
- Serum and plasma (long-term) [ Time Frame: 4 months to 12 months after CO poisoning ] [ Designated as safety issue: No ]Serum and plasma collected 4 months to 12 months after poisoning
Biospecimen Retention: Samples With DNA
Blood for plasma, serum, and DNA sequestration
|Study Start Date:||February 2012|
|Estimated Study Completion Date:||December 2018|
|Estimated Primary Completion Date:||December 2018 (Final data collection date for primary outcome measure)|
Patients with acute CO poisoning. Blood collection for biorepository only, no study intervention.
Other: No study intervention
There is no study-related intervention.
The investigators propose to establish a biorepository for storage of serum, plasma, and DNA collected from patients with carbon monoxide (CO) poisoning. Participants will also be evaluated for clinical outcome. The biorepository will include serum and plasma from CO-poisoned patients drawn at the time of injury as well as from blood drawn at clinical follow-up visits. The biorepository will also bank DNA from these participants.
These specimens can be analyzed in the future to elucidate potential inflammatory and immunological mechanisms that cause brain and heart damage and identify possible biological and genetic predictors of poor outcome.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01758653
|United States, Utah|
|Intermountain Medical Center|
|Murray, Utah, United States, 84107|
|Salt Lake City, Utah, United States, 84143|
|Principal Investigator:||Lindell K. Weaver, MD||Intermountain Health Care, Inc.|